⌘K

Login Start Free

Home/Filings/4/0000875320-25-000115

4//SEC Filing

Tatsis Ourania 4

Accession 0000875320-25-000115

CIK 0000875320other

View on SEC.gov Company Profile

Filed

Feb 25, 7:00 PM ET

Accepted

Feb 26, 4:15 PM ET

Size

6.1 KB

Accession

0000875320-25-000115

Insider Transaction Report

Form 4

Period: 2025-02-24

VERTEX PHARMACEUTICALS INC / MAVRTX

EVP, Chief Reg. & Quality Off.

Transactions

Tax Payment
Common Stock
2025-02-24$483.28/sh−3,310$1,599,657→ 64,385 total
Sale
Common Stock
2025-02-25$480.95/sh−354$170,256→ 64,031 total

Footnotes (1)

[F1]Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 02/29/2024.

Documents

1 file

4
wk-form4_1740604500.xmlPrimary
FORM 4

Issuer

VERTEX PHARMACEUTICALS INC / MA

CIK 0000875320

Entity typeother

Related Parties

1

filerCIK 0001789815

Filing Metadata

Form type: 4
Filed: Feb 25, 7:00 PM ET
Accepted: Feb 26, 4:15 PM ET
Size: 6.1 KB

View on SEC.gov